Application of real options analysis for pharmaceutical R&D project valuation-Empirical results from a survey

Research Policy

Volumn 35, Issue 3, 2006, Pages 343-354

  Hartmann, Marcus ^a   Hassan, Ali ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Investment analysis; Pharmaceutical industry; Project valuation; R D; Real options

Indexed keywords

DRUG PRODUCTS; FINANCE; HEALTH CARE; INVESTMENTS; RISK ASSESSMENT;

INVESTMENT ANALYSIS; PHARMACEUTICAL INDUSTRY; PROJECT VALUATION; R&D; REAL OPTIONS;

RESEARCH AND DEVELOPMENT MANAGEMENT;

EID: 33646058025     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2005.12.005     Document Type: Article

References (37)

1. Ashburn T.T., and Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nature Review Drug Discovery 3 (2004) 673-683
2. Black F., and Scholes M. The pricing of options and corporate liabilities. Journal of Political Economy 81 (1973) 637-659
3. Bode-Greul, K., 2000. Real options evaluation in pharmaceutical R&D: a new approach to financial project evaluation, Surrey.
4. Bolten B.M., and DeGregorio T. Trends in development cycles. Nature Reviews Drug Discovery 1 (2002) 335-336
5. Booth B., and Zemmel R. Prospects for productivity. Nature Reviews Drug Discovery 3 (2004) 451-456
6. Busby J.S., and Pitts C.G. Real options in practice: an explanatory survey of how finance officers deal with flexibility in capital appraisal. Management Accounting Research 8 (1997) 169-184
7. Cassimon D., Engelen P.J., Thomassen L., and Van Wouwe M. The valuation of a NDA using a 6-fold compound option. Research Policy 33 (2004) 41-51
8. Copeland, T., Antikarov, V., 2001. Real Options: A Practitioner's Guide, Texere.
9. Copeland T., and Tufano P. A real-world way to manage real options. Harvard Business Review 82 (2004) 90-99
10. Cox J., Ross S., and Rubinstein M. Option pricing: a simplified approach. Journal of Financial Economics 7 (1979) 229-264
11. Coy P. Exploiting uncertainty: the "real-options" revolution in decision-making. Business Week 7 (1999) 118
12. Geske R. The valuation of compound options. Journal of Financial Economics 7 (1979) 63-81
13. Gilbert, J., Henske, P., Singh, A., 2003. Rebuilding big pharma's business model. In Vivo: The Business & Medicine Report 21 (10), 1-10.
14. Grabowski H., and Vernon J. Longer patents for increased generic competition in the U.S.: the Waxman-Hatch Act after one decade. Pharmacoeconomics 10 (1996) 110-123
15. Howell S.D., and Jägle A.J. Laboratory evidence on how managers intuitively value real growth options. Journal of Business Finance and Accounting 24 (1997) 915-935
16. Jacob W.F., and Kwak Y.H. In search of innovative techniques to evaluate pharmaceutical R&D projects. Technovation 23 (2003) 291-296
17. Kaitin, K.I., 2003. Post-approval R&D raises total drug development costs to $ 897 million. Tufts Center for the Study of Drug Development Impact Report 2003, vol. 5.
18. Kellogg D., and Charnes J.M. Real options valuation for a biotechnology company. Financial Analysts' Journal 56 (2000) 76-87
19. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews Drug Discovery 3 (2004) 711-716
20. Krolle S., and Oßwald U. Wertorientierte Strategieberatung mit Real Option Valuation™. Finanzbetrieb 3 (2001) 233-239
21. Kumaraswamy, A., 1998. An organizational real-options perspective of firms' R&D: Empirical evidence. Paper presented at the Second Annual Conference on Real Options, Theory Meets Practice, Chicago, June, 1998.
22. Lun K., and Peske T. Anwendung des Tools noch zögerlich: Realoptionen. Wissenschaftsmanagement 8 (2002) 34-39
23. McGrath R.G., and Nerkar A. Real options reasoning and a new look at the investment strategies of pharmaceutical firms. Strategic Management Journal 25 (2004) 1-21
24. Merton R.C. Theory of rational option pricing. Bell Journal of Economics and Management Science 4 (1973) 141-183
25. Mohr, R., Pacl, H., Hartmann, M., in press. Realize hidden value through timely portfolio decisions. Research Technology Management.
26. Myers S.C. Financial theory and financial strategy. Interfaces 14 (1984) 126-137
27. Newton D.P., Paxson D.A., and Widdicks M. Real R&D options. International Journal of Management Reviews 5/6 (2004) 113-130
28. Nichols N. Scientific management at Merck: an interview with CFO Judy Lewent. Harvard Business Review 72 (1994) 89-99
29. Pavlou A.K., and Belsey M.J. Biopharma licensing and M&A trends. Nature Reviews Drug Discovery 4 (2005) 273-274
30. Remer S., Ang S.H., and Baden-Fuller C. Dealing with uncertainties in the biotechnology industry: the use of real options reasoning. Journal of Commercial Biotechnology 8 (2001) 95-105
31. Ryan P.A., and Ryan G.P. Capital budgeting practices of the Fortune 1000: How have things changed?. Journal of Business and Management 8 (2002) 355-364
32. Sellers L.J. Fourth annual Pharm Exec Top 50. Pharmaceutical Executive 23 (2003) 42-52
33. Sellers L.J. Pharm Exec 50. Pharmaceutical Executive 24 (2004) 60-67
34. Smith J.E., and Nau R.F. Valuing risky projects: Option pricing theory and decision analysis. Management Science 41 (1995) 795-816
35. Teach, E., 2003. Will options take root? CFO online, July 1st, pp. 73-76.
36. Vollrath, R., 2001. Die Berücksichtigung von Handlungsflexibilität bei Investitionsentscheidungen - Eine empirische Untersuchung, in: Hommel, U., Scholich, M., Vollrath, R. (Eds.), Berlin.
37. Woerner S.D., and Grupp H. The derivation of R&D return indicators within a real options framework. R&D Management 33 (2003) 313-325